Phosphoproteomics involves the large-scale study of phosphorylated proteins. Protein phosphorylation is a critical step in many signal transduction pathways and is tightly regulated by kinases and phosphatases. Therefore, characterizing the phosphoproteome may provide insights into identifying novel targets and biomarkers for oncologic therapy. Mass spectrometry provides a way to globally detect and quantify thousands of unique phosphorylation events. However, phosphopeptides are much less abundant than non-phosphopeptides, making biochemical analysis more challenging. To overcome this limitation, methods to enrich phosphopeptides prior to the mass spectrometry analysis are required. We describe a procedure to extract and digest proteins from tissue to yield peptides, followed by an enrichment for phosphotyrosine (pY) and phosphoserine/threonine (pST) peptides using an antibody-based and/or titanium dioxide (TiO 2 )-based enrichment method. After the sample preparation and mass spectrometry, we subsequently identify and quantify phosphopeptides using liquid chromatography-mass spectrometry and analysis software.
Introduction
An estimated 165,000 new cases and approximately 29,000 deaths will occur in 2018 due to prostate cancer, representing the most common cancer and second leading cause of cancer-related death in men in the United States 1 . Early stages of prostate cancer are treatable with resection or radiation therapy of organ-confined disease, where the ten-year recurrence rate is between 20% and 40% for patients who undergo prostatectomy and between 30% and 50% for patients who receive radiation therapy 2 . Because prostate cancer relies on androgen signaling for growth, surgical and chemical castration therapies are also employed for high-risk patients. However, relapse occurs when the cancer no longer responds to androgen deprivation therapy as evidenced by biochemical recurrence, where the prostate-specific antigen in serum rises again. At this point in the progression, metastases are often detected as well. This advanced stage, called metastatic castration-resistant prostate cancer, represents the lethal form of the disease where the prognosis is a median survival time of less than two years 3 . Few treatment options are available in late-stage disease, including second-generation antiandrogens such as enzalutamide and abiraterone, as well as taxane-based chemotherapy like docetaxel. Despite available treatments, the disease often progresses. Therefore, the discovery and development of novel treatment modalities are necessary to improve the care of prostate cancer patients with advanced disease.
Mass spectrometry (MS)-based approaches provide a global analysis of the proteome through the detection of hundreds to thousands of peptide analytes 4 . In particular, discovery proteomics, also known as data-dependent acquisition (DDA), can yield the identification and quantitation of thousands of peptides 4, 5 . MS-based discovery proteomics can be further delineated into top-down proteomics, where intact proteins are characterized, and bottom-up (also known as shotgun) proteomics, where peptides are analyzed to characterize proteins 5 . Thus, in shotgun proteomics, a proteolysis step takes place in the sample preparation preceding the MS analysis to cleave proteins into peptides. At the end, a database search is performed to map the peptides back to the proteins for identification. Label-free as well as several isotope-labeling [e.g., stable isotope labeling by amino acids in cell culture (SILAC)] methods can be used to quantitatively compare peptides between samples . Label-free quantitation provides greater coverage and permits comparisons between many more samples, whereas label-based methods are limited by cost and multiplexing capacities 6, 7, 8 . Furthermore, shotgun MS can be also used to interrogate post-translational modifications (PTMs) such as phosphorylation 11 . Due to the lower stoichiometric nature of phosphopeptides compared to total peptides, several methods are employed to enrich for phosphopeptides, including antibody-based immunoprecipitation of phosphotyrosine (pY) peptides, titanium dioxide (TiO 2 ), and immobilized metal affinity chromatography (IMAC) 5, 12 . Because protein phosphorylation is a key step in many cell signaling pathways, shotgun phosphoproteomics allows researchers to investigate cell signaling changes in different cancers, including breast 13 , prostate 14 , renal 15 , and ovarian, 16, 17 to better understand cancer biology and to identify potential new targets for therapy.
This label-free shotgun phosphoproteomic method was built and refined based on previous work by the Graeber group 18, 19, 20 . This protocol begins by describing the extraction and digestion of proteins and phosphoproteins from tissue into peptides. We then detail the enrichment of pY peptides using specific phosphotyrosine antibodies and TiO 2 . We also describe the enrichment of phosphoserine/threonine (pST) peptides using strong cation exchange (SCX) followed by TiO 2 . This protocol concludes with the submission of samples to an MS facility and the use of MS analysis software to identify and quantify phosphopeptides and their corresponding phosphoproteins. The application of this protocol can extend beyond prostate cancer into other cancers and fields outside of oncology.
Immunoprecipitation and Enrichment of pY Peptides 24
1. Resuspend the lyophilized powder with 0.5 mL of ice-cold immunoprecipitation (IP) binding buffer in each fraction. Pool the fractions by transferring the 0.5 mL resuspension volume from the second fraction to the first fraction and save the pipette tip. Vigorously vortex (instead of pipetting up and down) to make sure the sample is completely dissolved before transferring it to a 3.6 mL screw cap cryotube. 2. As in step 4.1., rinse the lyophilization tubes with another 0.5 mL of IP binding buffer ( 4. Add pre-washed pY beads to the resuspended sample solution in the screw cap cryotubes. Incubate them at 4 °C on an end-over-end rotator overnight. 5. Place the screw cap cryotubes in a 50 mL centrifuge tube lined with a delicate wipe. Spin down the beads at 100 x g for 1 min. Save the supernatant, which will be used to enrich for pST peptides. (The enrichment for pST begins at step 7 and can be performed in parallel to the pY peptide processing). 6. Resuspend the beads with 300 µL of IP binding buffer. Transfer them to a 2 mL microcentrifuge tube and spin them down at 100 x g for 1 min at 4 °C. 7. Rinse the incubation tube 3x with 200 µL of IP binding buffer. Transfer the contents to the same Microcentrifuge tube each time. Then spin them down. 8. Wash the beads in the microcentrifuge tube 3x with 500 µL of IP binding buffer and spin them down at 100 x g for 1 min. Then wash the beads 4x with 450 µL of 25 mM NH 4 HCO 3 , pH 7.5, and spin them down at 100 x g for 1 min. Use a fresh 25 mM NH 4 HCO 3 solution from powder every time. 9. Centrifuge the beads at 1,500 x g for 1 min. Use a gel-loading tip to remove the supernatant completely by dipping the tip of the gel-loading tip slightly below the beads' surface. 10. Add 4x the bead volume of 0.1% TFA to the beads (i.e., add 300 µL of 0.1% TFA for 75 µg of pY bead slurry). Mix them well and incubate the mixture in a thermomixer at 1,000 rpm for 15 min at 37 °C. 11. Transfer the resuspension to a 0.2 µm spin filter. Quickly spin down the elution tube and transfer the residual volume to the same spin filter using a P10 pipet. Spin down the spin filter at 850 x g for 1 min. Transfer the elution to a low protein-binding microcentrifuge tube. Vacuum concentrate the eluate to dryness overnight at 40 °C and with a heat time of 300 min. Note: The experiment can be paused here. Freeze the samples at -80 °C and continue at a later date.
Titanium Dioxide Enrichment 25 of pY Peptides
1. Resuspend the dried down phosphopeptides in 200 µL of 50% ACN, 0.1% TFA. Vortex and centrifuge them at 10,000 x g for 30 s. Repeat this 1x to resuspend them well. 2. Preparing the TiO 2 beads contained in tips that have a capacity for 200 µL samples.
1. Gently tap on the small tip-side of the tip to move the material to that end. Rinse the tip by adding 200 µL of 100% ACN, followed by inverting the tip and flicking the small end to move the liquid towards the cap. 2. Using a razor blade, cut the small tip of the tip and place it over a low protein-binding tube. (Avoid using polystyrene tubes as the TiO2 will stick to the sides of the tube.) Remove the cap and insert a micropipette to plunge out the remaining ACN. Repeat the wash with 200 µL of 100% ACN. The TiO2 beads are now located in the low protein-binding tube for the following steps. 3. Precondition TiO 2 with 500 µL of 100% ACN 2x. Pipet it to mix the beads with the solvent. Centrifuge them at 100 x g for 1 min. 4. Condition TiO 2 with 500 µL of 0.2 M sodium phosphate buffer (pH ~7) 2x. Wash the beads with 300 µL of equilibration buffer 3x.
Because TiO 2 is very dense, the beads will settle quickly.
Reverse Phase Extraction of pST Peptides
1. Measure the peptide concentration of the supernatant acquired from step 4.6 by performing a peptide assay. A sufficient amount for pST mass spectrometry is 2.5 mg. 2. Adjust pH to 3.5 with 5% TFA. 3. Connect the shorter end of a C-18 column to a vacuum manifold. Set the vacuum between 17 and 34 kPa (or according to the manufacturer's instructions). Wet the column with 3 mL of 100% ACN. Do not let the column dry. 4. Equilibrate the column with 6 mL of 0.1% TFA applied as 2x 3 mL. Load the acidified sample into the column. Do not add more than 3 mL at a time. Adjust the vacuum to target about 1 -2 drops per second. 5. Wash the column with 9 mL of 0.1% TFA applied as 3x 3 mL. Elute the column with 2 mL of 40% ACN, 0.1% TFA. Collect two 2 mL fractions into glass culture tubes. Discard the column. 6. Cover the eluate tubes with parafilm and punch 3 -5 holes on the cover using a 20G needle. Freeze the eluate on dry ice for at least 30 min until it is completely solid. 7. Lyophilize the selected fractions overnight. On the following day, make sure the samples are completely dry before stopping the lyophilizer.
Store the tubes in a 50 mL conical tube with delicate wipes at -80 °C. Note: The experiment can be paused here.
Strong Cation Exchange (SCX) of pST Peptides
1. Resuspend the lyophilized peptides in 2 mL of Buffer A ( Table 1) 
Titanium Dioxide Enrichment of pST Peptides Representative Results
This protocol describes in detail a method for protein extraction and digestion followed by phosphopeptide enrichment and subsequent MS analysis (Figure 1) . The compositions of all the buffers and solutions that are used in this protocol are listed in Table 1 . The sequential use of Lys-C and trypsin provides an efficient digestion. A Coomassie-stained gel of pre-digested lysate confirms the presence of proteins, while staining of post-digested lysate confirms the complete digestion (Figure 2A) . For a complete digestion, no bands should appear above 15 kDa, except the 30 kDa and 23.3 kDa bands for Lys-C and trypsin, respectively. The addition of Lys-C also reduces the number of missed cleavages ( Figure 2B) . Because pY peptides represent only 2% of the phosphoproteome 28 , immunoprecipitation of the pY peptides using a pY-specific antibody is the first step of pY peptide enrichment. The resulting supernatant becomes the input for pST peptide enrichment. The pY immunoprecipitation effectively separates pY peptides from pST peptides where on average 85% of the phosphopeptides identified from the pY preparation are pY ( Figure 3A) and over 99% of the phosphopeptides identified from the pST preparation are pST ( Figure 3B) . Titanium dioxide is used to enrich for phosphopeptides in both preparations. The expected percentage of peptides in the MS-ready preparation that are phosphorylated is between 30 -50% ( Figure 4A) . The variability in the phosphopeptide enrichment percentage may be greater in the pY preparation as a result of there being many fewer pY peptides than pST peptides. In terms of phosphopeptide species, the majority of the phosphopeptides detected have a single or double phosphoryl group (Figure 4B) .
After performing mass spectrometry, the MS raw files are loaded into an MS analysis software. The parameter settings used in the experiment are listed in Table 3 but will vary from software to software and may vary from version to version. The parameters that are not listed were left as default, including an FDR cutoff of 1% for peptide-spectrum matching (PSM) with a minimum Andromeda score of 40 for the identification of modified peptides 27 . Setting a localization probability cutoff of greater than 0.75 filters out approximately 5% of the pY peptides and 15% and 34% of the pS and pT peptides, respectively ( Figure 5A ). After applying these filters, the expected number of phosphopeptide identifications at the end of the MS analysis is approximately 300 pY peptides (for 5 mg of the starting protein) and about 7,500 pS peptides and 640 pT peptides (for 2.5 mg of the starting peptide amount) from the respective enrichment preparations (Figure 5B) . The number of replicates and the variability of the phosphopeptide signal intensity determines adequate powering for statistical comparisons. In four separate experiments with groups containing either biological duplicates or triplicates, the percent coefficients of variation (%CV) for detected phosphopeptides were calculated. Distributions of lower variability (e.g., pST groups 1 -5 in Figure 5C ) indicate that the sample collection, preparation, and mass spectrometry runs were consistent. On the other hand, distributions of higher variability (e.g., pST group 6 in Figure 5C ) indicates noisier data that would require larger fold-changes to detect significant differences in downstream differential analyses. 6 M guanidinium chloride lysis buffer 50 mL 6 M guanidinium chloride, 100 mM tris pH 8.5, 10 mM tris (2-carboxyethyl) phosphine, 40 mM chloroacetamide, 2 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 500 mg n-octyl-glycoside, ultra-pure water to volume 100 mM sodium pyrophosphate 50 mL 2.23 g sodium pyrophosphate decahydrate, ultra-pure water to volume 1M β-glycerophosphate 50 mL 15.31 g β-glycerophosphate, ultra-pure water to volume 5% trifluoroacetic acid 20 mL Add 1 mL of 100% trifluoroacetic acid into 19 mL ultra-pure water 0.1% trifluoroacetic acid 250 mL Add 5 mL 5% trifluoroacetic acid to 245 mL ultra-pure water pY elution buffer 250 mL 0.1% trifluoroacetic acid, 40% acetonitrile, ultra-pure water to volume pST elution buffer 250 mL 0.1% trifluoroacetic acid, 50% acetonitrile, ultra-pure water to volume IP binding buffer 200 mL 50 mM tris pH 7.4, 50 mM sodium chloride, ultra-pure water to volume 25 mM ammonium bicarbonate, pH 7.5 10 mL Dissolve 19.7 mg into 10 mL sterile ultra-pure water, pH to 7.5 with 1 N hydrochloric acid (~10-15 µL/10 ml solution), make fresh 1M phosphate buffer, pH 7 1,000 mL 423 mL 1 M sodium dihydrogen phosphate, 577 mL 1 M sodium hydrogen phosphate
Equilibration buffer 14 mL 6.3 mL acetonitrile, 280 µL 5% trifluoroacetic acid, 1740 µL lactic acid, 5.68 mL ultra-pure water Rinsing buffer 20 mL 9 mL acetonitrile, 400 µL 5% trifluoroacetic acid, 10.6 mL ultra-pure water
Mass spectrometry solution 10 mL 500 µL acetonitrile, 200 µL 5% trifluoroacetic acid, 9.3 mL ultra-pure water Buffer A 250 mL 5 mM monopotassium phosphate (pH 2.65), 30% acetonitrile, 5 mM potassium chloride,ultra-pure water to volume Buffer B 250 mL 5 mM monopotassium phosphate (pH 2.65), 30% acetonitrile, 350 mM potassium chloride, ultra-pure water to volume 0.9% ammonium hydroxide 10 mL 300 μL 29.42% ammonium hydroxide, 9.7 mL ultra-pure water Dynamic exclusion (s) 20 Table 2 : LC-MS settings. This is an example of LC-MS settings in a typical shotgun phosphoproteomic experiment. The samples were loaded on to a trap column. The trap was brought in-line with an analytical column. These settings were optimized for using the LC-MS system listed in the 
LC-MS/MS

Discussion
Before utilizing this protocol to enrich for phosphopeptides, a careful consideration of the experimental design is critical. Using biological replicates is a more cost-effective use of mass spectrometry resources than technical replicates. The number of replicates that are necessary will depend in part on the variability of the data. A recent study demonstrated that, while increasing the number of replicates beyond three only marginally increases the number of identifications, the number of significant identifications between groups increases with more replicates 10 .
Due to the lower abundance of phosphoproteins in the cell, sufficient starting protein amounts are necessary to obtain a global phosphoproteome from prostate cancer samples in discovery mode. In these experiments, 5 mg of protein was used. Approximately five nearly confluent 15-cm dishes of cells provide enough protein as input into this protocol, although this will be cell line-dependent. As for tumor tissue, the expected yield of protein is about 6 -8% of tissue weight. In the in vitro setting, a positive control sample to consider is the addition of 1 mM vanadate for 30 min before harvesting the cells. Vanadate, a competitive protein phosphotyrosyl phosphatase inhibitor, will preserve the tyrosine phosphorylation, thus increasing the number of pY peptide identifications 29 .
Clean digestion is a key step to maximize phosphopeptide identification. In addition to the Coomassie stain test, the percent of missed cleavages in the data can be used to evaluate digestion efficiency (Figure 2) . Quality-control software is available that analyzes missed cleavages and other metrics to assess MS data quality 30 . While trypsin is the most common, alternative proteases are available 5 to address coverage gaps in the proteome where optimal tryptic peptides cannot be generated 31 . The settings of the MS analysis software would then need to be modified accordingly to adjust for changes in proteases.
The protocol employs immunoprecipitation (for pY enrichment) as well as titanium dioxide (TiO 2 ) to enrich for phosphopeptides. Alternative approaches to enrich for peptides include immobilized metal affinity chromatography (IMAC), other metal oxides for metal oxide affinity chromatography (MOAC) such as aluminum hydroxide, and polymer-based metal ion affinity capture (PolyMAC) 5, 12 . Previous studies have shown that different enrichment methods enrich for different populations of phosphopeptides 32 . For instance, IMAC enriches more multiphosphorylated peptides while MOAC preferably enriches for mono-phosphorylated peptides 33 . The Representative Results of this protocol reflect this observation ( Figure 4B) . A recent publication demonstrated that combining IMAC and MOAC using a hybrid material could potentially provide greater coverage of phosphopeptide species 34 . Thus, this protocol could be modified to utilize other enrichment methods in parallel to allow for even more comprehensive phosphoproteomic analyses.
The MaxQuant 26 software suite is used to analyze the MS data in this protocol, but commercial applications 35 are also available for phosphopeptide identification and quantification. For phosphopeptide identification, a localization probability cutoff is applied. This filter is performed to select for phosphopeptides with a high confidence (i.e., greater than 0.75) in phosphoresidue identification 10, 28 . In other words, the summed probability of all other residues that could potentially contain the phospho-group is less than 0.25. This cutoff could be raised to increase the stringency of the phosphopeptide selection. In regard to the number of identifications, the expected number of pY peptides is in the hundreds, while the expected number of pST peptides is in the high thousands. These values reflect previously observed phosphoproteome distribution where about 2%, 12%, and 86% of the phosphosites are pY, pT, and pS, respectively 28 .
If the pY and pST enrichment steps are performed in parallel, the sample preparation steps in the protocol can be completed in six days. By pairing with the powerful tool of MS, phosphopeptide enrichment protocols such as this provide a global approach for scientists to collect data to analyze the phosphoproteome in their respective research fields.
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